Table 2 Comparison of the study population with children receiving conventional therapies from the 2 European registers.
From: A nationwide experience of biological treatments in children with eosinophilic esophagitis
EOSINOBIO (N = 36) | pEEr (N = 582) | p | EoE Connect (N = 254) | p | |
|---|---|---|---|---|---|
Demographics | |||||
Age at EoE diagnosis (year) | |||||
\(\bullet\) mean ± SD | 7.4 ( ± 4.4) | 11.9 ( ± 3.9) | N/A | ||
\(\bullet\) median [IQR] | 7.5 [3.0; 11.0] | 10.5 [5.7; 17.3] | N/A | ||
Male gender (%) | 27 (75.0) | 355/582 (61.0) | 0.09 | 206 (84.1) | 0.44 |
Comorbidities | |||||
Atopic dermatitis | 17 (47.2) | 153 (26.3) | 0.006 | 57 (22.4) | 0.0014 |
Food allergy | 23 (63.9) | 187 (32.1) | <0.0001 | N/A | N/A |
Asthma | 26 (72.2) | 151 (25.9) | <0.0001 | 79 (31.1) | <0.0001 |
Allergic rhinitis | 14 (38.9) | 203 (34.9) | 0.6 | 124 (48.8) | 0.3 |
Symptoms at diagnosis | |||||
Food impaction | 24 (66.6) | 99 (17.0) | <0.0001 | 111 (46.1) | 0.009 |
Dysphagia | 21 (58.3) | 145 (25.0) | <0.0001 | 141 (58.5) | 0,7 |
Vomiting | 17 (47.2) | 93 (16.0) | <0.0001 | 47 (19.5) | <0.0001 |
Regurgitations | 12 (33.3) | N/A | N/A | 24 (10.0) | <0.0001 |
Abdominal pain | 12 (33.3) | 87 (15.0) | 0.0035 | 33 (13.7) | 0.0016 |
Failure to thrive | 12 (33.3) | 76 (13.0) | 0.0007 | 26 (10.8) | 0.0001 |
Endoscopic findings at diagnosis | |||||
Peak of eosinophils/HPF, median [IQR] | |||||
▪ Proximal | 20 [13; 40]a | 43 [40; 51] | N/A | N/A | N/A |
▪ Mid | 20 [15; 40]b | 40 [36; 49] | |||
▪ Distal | 25 [15; 40]c | 45 [37; 65] | |||
EREFS score median ± IQR | 3.0 ± 1.0d | N/A | N/A | 3.0 ± 2.0f | N/A |
Edema | 14 (43.8)d | N/A | N/A | N/A | N/A |
Ring | 11 (34.4)d | 134 (23.0) | 0.3 | N/A | N/A |
Exudate | 21 (67.7)c | 221 (38.0) | 0.0002 | N/A | N/A |
Furrows | 20 (64.5)c | 187 (32.0) | 0.06 | N/A | N/A |
Stricture | 9 (27.3)e | N/A | N/A | 16 (6.9) | 0.0002 |
